Cochlear’s CEO & President, Dig Howitt said, “The positive momentum we have experienced across the developed markets over the past few years has continued into FY18 with a 12% increase in cochlear implant units delivered across these markets.
“Cochlear’s market leadership position has strengthened with new products broadening the portfolio and driving share gains. Over the past 18 months we have released the Nucleus® 7 Sound Processor, the world’s first Made for iPhone cochlear implant sound processor, the Kanso® Sound Processor, our first off-the-ear sound processor, the Nucleus® Profile Slim Modiolar (CI532) electrode, the world’s slimmest electrode, and the Baha® 5 SuperPower Sound Processor, with strong demand experienced for each product.
“The Nucleus 7 Sound Processor was launched during the second quarter across key markets including the US, Western Europe and Australia, performing well in its first three months. The technology allows users to stream sound from an iPhone® , iPad® and iPod touch® directly to their sound processor, offering greater accessibility, connectivity and wireless solutions.
“Emerging market implant units reduced during the half primarily as a result of the timing of a number of tenders. In particular, the HY17 result included 1,100 Chinese Central Government tender units. We expect to start shipping the 1,491 China tender units awarded in October 2017 during the second half.
“The Services business delivered CC revenue growth of 12% driven by the release of the Nucleus 7 Sound Processor and the first time inclusion of Sycle revenue. The Acoustics business delivered sales growth of 5% in CC with solid demand continuing for the Baha® 5 range of sound processors.”
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.